Hideki Suganami

2.8k total citations
85 papers, 2.2k citations indexed

About

Hideki Suganami is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Hideki Suganami has authored 85 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Molecular Biology, 36 papers in Endocrinology, Diabetes and Metabolism and 33 papers in Surgery. Recurrent topics in Hideki Suganami's work include Diabetes Treatment and Management (29 papers), Lipoproteins and Cardiovascular Health (19 papers) and Peroxisome Proliferator-Activated Receptors (17 papers). Hideki Suganami is often cited by papers focused on Diabetes Treatment and Management (29 papers), Lipoproteins and Cardiovascular Health (19 papers) and Peroxisome Proliferator-Activated Receptors (17 papers). Hideki Suganami collaborates with scholars based in Japan, United States and Australia. Hideki Suganami's co-authors include Eiichi Araki, Koutaro Yokote, Shun Ishibashi, Shizuya Yamashita, Hidenori Arai, Tetsuya Yamamoto, Hidenobu Tanihara, Yasuaki Kuwayama, Haruki Abe and Makoto Araie and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Hideki Suganami

84 papers receiving 2.2k citations

Peers

Countries citing papers authored by Hideki Suganami

Since Specialization

Citations

This map shows the geographic impact of Hideki Suganami's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hideki Suganami with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hideki Suganami more than expected).

Fields of papers citing papers by Hideki Suganami

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hideki Suganami. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hideki Suganami. The network helps show where Hideki Suganami may publish in the future.

Co-authorship network of co-authors of Hideki Suganami

This figure shows the co-authorship network connecting the top 25 collaborators of Hideki Suganami. A scholar is included among the top collaborators of Hideki Suganami based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hideki Suganami. Hideki Suganami is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Effects of Extended-Release Pemafibrate Tablets on Dyslipidemia and Safety in Triglyceridemic Patients: A Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group Study 2025 ·Journal of Atherosclerosis and Thrombosis ·Hidenori Arai, Shizuya Yamashita, Eiichi Araki, Koutaro Yokote, Ryohei Tanigawa, Ayumi Saito, Daisuke Furukawa, Hideki Suganami, Shun Ishibashi	3
2	Drug–drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open‐label, randomized, 6‐sequence, 3‐period crossover studies 2024 ·Clinical and Translational Science ·(unknown), Neil Hounslow, Hideki Suganami, Ryohei Tanigawa	1
3	Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial 2024 ·Journal of Atherosclerosis and Thrombosis ·Hidenori Arai, Shizuya Yamashita, Eiichi Araki, Koutaro Yokote, Ryohei Tanigawa, Ayumi Saito, (unknown), Hideki Suganami, Shun Ishibashi	4
4	Pharmacokinetics and Safety of Pemafibrate in Patients with both Dyslipidemia and Severe Renal Impairment: A Phase 4 Study 2024 ·Journal of Atherosclerosis and Thrombosis ·Shun Ishibashi, Hidenori Arai, Koutaro Yokote, Eiichi Araki, (unknown), (unknown), (unknown), Hideki Suganami, (unknown), Shizuya Yamashita	1
5	Clinical Pharmacology of Pemafibrate Extended-release Formulation in Patients with Hypertriglyceridemia—A Phase 2, Multicenter, Active-controlled, Randomized, Single-blind, Crossover study 2024 ·Journal of Atherosclerosis and Thrombosis ·Shizuya Yamashita, Eiichi Araki, Hidenori Arai, Koutaro Yokote, Ryohei Tanigawa, Ayumi Saito, Hideki Suganami, (unknown), Shun Ishibashi	2
6	Effects of Pemafibrate on LDL-C and Related Lipid Markers in Patients with MASLD: A Sub-Analysis of the PEMA-FL Study 2024 ·Journal of Atherosclerosis and Thrombosis ·Ryohei Tanigawa, Atsushi Nakajima, Yuichiro Eguchi, Hirokazu Takahashi, Rohit Loomba, Hideki Suganami, (unknown), Ayumi Saito, Yuki Iida, Shizuya Yamashita	4
7	Crossover Randomized Study of Pharmacologic Effects of Ripasudil–Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine 2023 ·Advances in Therapy ·Hidenobu Tanihara, Tetsuya Yamamoto, Makoto Aihara, Noriko Koizumi, (unknown), Satoshi Kojima, Tomoyuki Isobe, (unknown), Hideki Suganami, (unknown), Hiroshi Mikami, (unknown), Hidetoshi Furuie, (unknown), (unknown), (unknown), (unknown), Makoto Ando, (unknown)	10
8	Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial 2023 ·Journal of Atherosclerosis and Thrombosis ·Kenichi Tsujita, Koutaro Yokote, Junya Ako, Ryohei Tanigawa, (unknown), Hideki Suganami	5
9	Ripasudil–Brimonidine Fixed-Dose Combination vs Ripasudil or Brimonidine: Two Phase 3 Randomized Clinical Trials 2022 ·American Journal of Ophthalmology ·Hidenobu Tanihara, Tetsuya Yamamoto, Makoto Aihara, (unknown), Satoshi Kojima, (unknown), (unknown), Hideki Suganami	16
10	Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease 2021 ·Alimentary Pharmacology & Therapeutics ·Atsushi Nakajima, Yuichiro Eguchi, Masato Yoneda, Kento Imajo, Nobuharu Tamaki, Hideki Suganami, (unknown), Ryohei Tanigawa, (unknown), Yuki Iida, Rohit Loomba	144
11	Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial 2017 ·Journal of clinical lipidology ·Shun Ishibashi, Hidenori Arai, Koutaro Yokote, Eiichi Araki, Hideki Suganami, Shizuya Yamashita	147
12	Specific clinical features of intraocular pressure-lowering effect in ripasudil (K-115): insights from 52-week phase 3 study 2016 ·Investigative Ophthalmology & Visual Science ·Hidenobu Tanihara, Toshihiro Inoue, Tetsuya Yamamoto, Yasuaki Kuwayama, Haruki Abe, Atsuki Fukushima, Hideki Suganami, Makoto Araie	1
13	Current Practice on Multiplicity Adjustment and Sample Size Calculation in Multi-arm Clinical Trials: An Industry Survey in Japan 2016 ·Therapeutic Innovation & Regulatory Science ·Kentaro Sakamaki, (unknown), (unknown), (unknown), Seitaro Yoshida, (unknown), (unknown), (unknown), Hideki Suganami	2
14	Abstract 13374: Efficacy and Safety of K-877, a Potent and Selective PPAR-α Modulator (SPPARMα), in Combination With Statins in Japanese Patients With Dyslipidemia 2015 ·Circulation ·Hidenori Arai, Shun Ishibashi, Shizuya Yamashita, Eiichi Araki, Koutaro Yokote, Hideki Suganami, Tatsuhiko Kodama	6
15	Establishing Statisticians Standards of Conduct— Background and Tasks for the Future 2014 ·Keiko Sato, Manabu Iwasaki, Hideki Suganami, Toshiya Sato, Hiroe Tsubaki	1
16	Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study 2014 ·Cardiovascular Diabetology ·Kohei Kaku, Hirotaka Watada, Yasuhiko Iwamoto, Kazunori Utsunomiya, Yasuo Terauchi, Kazuyuki Tobe, Yukio Tanizawa, Eiichi Araki, Masamichi Ueda, Hideki Suganami, Daisuke Watanabe, (unknown)	172
17	Intra‐ocular pressure‐lowering effects of a Rho kinase inhibitor, ripasudil (K‐115), over 24 hours in primary open‐angle glaucoma and ocular hypertension: a randomized, open‐label, crossover study 2014 ·Acta Ophthalmologica ·Hidenobu Tanihara, Toshihiro Inoue, Tetsuya Yamamoto, Yasuaki Kuwayama, Haruki Abe, Hideki Suganami, Makoto Araie	103
18	QT PRODACT: Inter-facility Variability in Electrocardiographic and Hemodynamic Parameters in Conscious Dogs and Monkeys 2005 ·Journal of Pharmacological Sciences ·Hiroyuki Sasaki, (unknown), Hideki Suganami, Keiji Yamamoto	28
19	QT PRODACT: Inter- and Intra-facility Variability of the Action Potential Assay Using Isolated Guinea-Pig Papillary Muscles 2005 ·Journal of Pharmacological Sciences ·(unknown), Masayuki Yamada, Kazuo Kobayashi, (unknown), (unknown), (unknown), Tatsuya Mori, Hideki Suganami, Keiji Yamamoto	4
20	Designing a multistage, SNP-based, genome screen for common diseases 2004 ·Journal of Human Genetics ·Yasunori Sato, Hideki Suganami, Chikuma Hamada, Isao Yoshimura, Teruhiko Yoshida, Kimio Yoshimura	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact